NCT01349998

Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis

An Open-Label Study to Evaluate the Safety of Long-Term Administration of Product 33525 in Subjects With Tinea Pedis, Tinea Corporis, or Tinea Cruris

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 604 (actual)
• Sponsor: Tinea Pharmaceuticals · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to examine the long-term safety of treating recurrent episodes of tinea pedis for 14 days for each recurrence and recurrent episodes of tinea corporis or tinea cruris for 7 days for each recurrence with Product 33525.

Conditions

• Tinea Pedis
• Tinea Cruris
• Tinea Corporis

Interventions

Type	Name	Description
DRUG	Product 33525	Daily dosing for 2 weeks each recurrence for patients with tinea pedis and Daily dosing for 1 week each recurrence for patients with tinea cruris and tinea corporis

Timeline

• Start date: 2011-05-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2011-05-09
• Last updated: 2013-01-23

Locations

24 sites across 5 countries: United States, Belize, El Salvador, Honduras, Puerto Rico